Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 58 min ago
PreprintAll rights reservedmedRxiv

P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy

  • M. A. Brimble
  • S. Tan
  • S. Buddle
  • L.-A. K. Brown
  • J. Breuer
  • J. C. Crawford1
  1. 1St. Jude Children's Research Hospital
Read full textPDFDOICite

Related

  1. Competing Mortality, Not Breast-Cancer Mortality, Explains the Survival Deficit of Breast Cancer After a Prior Non-Breast Cancer: A SEER Competing-Risks Analysis
    İsmail Zihni, Burcu Zihni, İmren Mutlu +2
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Effect of Antibiotic Incorporation on the Porosity of Polymethylmethacrylate (PMMA) Bone Cement: A Comparative Analysis
    Paraskevas Georgoulas, Efthymios Iliopoulos, Ioannis Vasios +5
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Marine primary production enhances removal of hydrophobic organic contaminants from Eurasian Arctic shelf waters
    Xiaodi Shi, Laurent Oziel, Jonathan P. Benskin +2
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  4. Microplastics as Emerging Contaminants: Pathways, Environmental Persistence, and Human Health Implications
    Jana Rammal, Assi Al Moussawi, Chaden Haidar +4
    MicroplasticsPeer-reviewedCC BY 4.0Full text1 citedEcologyMaterials & polymersHAL
  5. Combined toxicity of cyanotoxins and anthropogenic contaminants on Chlorella vulgaris: insights from single and binary mixture exposures.
    Carlos Pinheiro, Joana Azevedo, Alexandre Campos +3
    Ecotoxicology (London, England)Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@misc{brimble2026promotermediated,
  title = {{P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy}},
  author = {M. A. Brimble and S. Tan and S. Buddle and L.-A. K. Brown and J. Breuer and J. C. Crawford},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.10.26362787},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.10.26362787v1},
}
RIS
TY  - UNPB
TI  - P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy
AU  - M. A. Brimble
AU  - S. Tan
AU  - S. Buddle
AU  - L.-A. K. Brown
AU  - J. Breuer
AU  - J. C. Crawford
PY  - 2026
DA  - 2026/09/10
PB  - medRxiv
DO  - 10.64898/2026.09.10.26362787
UR  - https://www.medrxiv.org/content/10.64898/2026.09.10.26362787v1
ER  -